FDA panel confronting peptide controversy

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The FDA is weighing a politically charged decision on compounded peptides, Revolution Medicines is advancing a promising pancreatic cancer drug toward approval, and new evidence suggests Merck’s Ebola vaccine may help blunt the DRC’s Bundibugyo outbreak.

The need-to-know this morning

Earnings season rolls on, with Roche and Argenx reporting this morning.

Verdiva Bio, which is working on obesity drugs, has hired Steve Marso as chief medical officer. He was previously CMO at Metsera, the obesity-focused biotech that Pfizer acquired last year.

FDA panel confronting peptide controversy

Other newsrooms on this story

Related reading

FDA panel considers easing peptide restrictions

UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm

FDA panel reviewing some peptides to consider loosening regulations for…

FDA Set To Review Safety And Access To Peptides: What You Need To Know

Peptides get their regulatory closeup

FDA advisory committee for peptides stocked with conflicts of interest